Literature DB >> 7038090

In vitro studies on the metabolic pathway of SQ 14225 (Captopril) and mechanism of mixed disulfide formation.

T Komai, T Ikeda, K Kawai, E Kameyama, H Shindo.   

Abstract

The metabolic pathway of SQ 14225 (Captopril) and the mechanism of the mixed disulfide formation with endogenous sulfhydryl compounds were studied in in vitro cell free systems. In the rat liver 9000 x g supernatants, SQ 14225-14C was metabolized to one major metabolite, glutathione-SQ 14225 mixed disulfide (GSSQ), and two minor metabolites including SQ 14551, a symmetrical disulfide of SQ 14225. The formation of GSSQ was markedly accelerated by the addition of oxidized glutathione (GSSG), but not affected by the addition of reduced glutathione (GSH), indicating that GSSQ was formed by the thiol-disulfide interchange between SQ 14225 and GSSG. Although the thiol-disulfide interchange was also observed between SQ 14225 and L-cystine, L-homocystine and SQ 14551 as well as GSSG, only the formation of GSSQ was a rapid reaction and markedly decreased by heat treatment of the liver 9000 x g supernatants. These findings demonstrate that the formation of GSSQ is catalyzed by a GSSG specific enzyme which is supposed to be thioltransferase (Glutathione: Disulfide Oxidoreductase). Although GSSQ was stable in the rat liver 9000 x g supernatants, it was rapidly hydrolyzed to cysteine-SQ 14225 mixed disulfide (CySSQ) in the rat kidney 9000 x g supernatants. A specific inhibitor of gamma-glutamyltranspeptidase, anthglutin, inhibited the hydrolysis. GSSQ-14C administered to a beagle dog was excreted into the urine in the form of CySSQ. Thus, it was speculated that CySSQ excreted into the urine as a major metabolite of SQ 14225 was derived from GSSQ formed in the liver followed by hydrolysis in the kidney.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7038090     DOI: 10.1248/bpb1978.4.677

Source DB:  PubMed          Journal:  J Pharmacobiodyn        ISSN: 0386-846X


  7 in total

Review 1.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

2.  Gastrointestinal transit and systemic absorption of captopril from a pulsed-release formulation.

Authors:  I R Wilding; S S Davis; M Bakhshaee; H N Stevens; R A Sparrow; J Brennan
Journal:  Pharm Res       Date:  1992-05       Impact factor: 4.200

3.  Investigation of the Captopril-Insulin Interaction by Mass Spectrometry and Computational Approaches Reveals that Captopril Induces Structural Changes in Insulin.

Authors:  Amrita Ghosh; Aiswarya B Pawar; Tejas Chirmade; Swaraj M Jathar; Rahul Bhambure; Durba Sengupta; Ashok P Giri; Mahesh J Kulkarni
Journal:  ACS Omega       Date:  2022-06-30

4.  The pharmacokinetics of captopril and captopril disulfide conjugates in uraemic patients on maintenance dialysis: comparison with patients with normal renal function.

Authors:  O H Drummer; B S Workman; P J Miach; B Jarrott; W J Louis
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 5.  Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review.

Authors:  S H Kubo; R J Cody
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

Review 6.  Captopril: an update review of its pharmacological properties and therapeutic efficacy in congestive heart failure.

Authors:  J A Romankiewicz; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-01       Impact factor: 9.546

7.  Intestine-Specific, Oral Delivery of Captopril/Montmorillonite: Formulation and Release Kinetics.

Authors:  Suguna Lakshmi Madurai; Stella Winnarasi Joseph; Asit Baran Mandal; John Tsibouklis; Boreddy Sr Reddy
Journal:  Nanoscale Res Lett       Date:  2010-08-27       Impact factor: 4.703

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.